Recent Updates
Recently added Catalysts

CYWC628

Phase 1

Diabetic Foot Ulcer (DFU) | Monoclonal antibody | Metabolic |FibroBiologics, Inc.|Last Updated: Aug 26, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment120

FDA Designations

No designations recorded

Clinical trial landscape

CYWC628 · 1 trial · 1 indication

Phase 1 1
NCT07096934Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of CareDiabetic Foot Ulcer (DFU)
RECRUITING120 Analytics
PHASE1RECRUITING
Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care
Diabetic Foot Ulcer (DFU)Unlock trial analytics

Study Endpoints

Primary Endpoints

Evaluate Adverse events, including severity grading using Common Terminology Criteria for Adverse Events (CTCAE v5.0), and relationship to treatment
from enrollment to the end of the treatment at 12 weeks

Evaluate the safety and tolerability of Standard of Care (SoC) + CYWC628 in patients with diabetic foot ulcer (DFU) as compared to SoC only. • Adverse events, including severity grading using Common Terminology Criteria for Adverse Events (CTCAE v5.0), and relationship to treatment.

Evaluate proportion of participants with complete wound closure by 12 weeks after commencing study treatment or SoC
from enrollment to the end of the treatment at 12 weeks

Evaluate the efficacy of SoC + low dose and high dose CYWC628 in wound healing of DFU, compared with SoC only. Proportion of participants with complete wound closure by 12 weeks after commencing study treatment or SoC. Complete wound closure is defined as 100% re-epithelialization with no wound drainage, as determined by the Investigator, observed at 2 visits 2 weeks apart

Evaluate percentage area reduction (PAR) of the DFU wound during the 12 week treatment period.
from enrollment to the end of the treatment at 12 weeks

Evaluate the safety and tolerability of Standard of Care (SoC) + CYWC628 in patients with diabetic foot ulcer (DFU) as compared to SoC only. Percentage area reduction (PAR) of the DFU wound during the 12 week treatment period.

Secondary Endpoints

Evaluate the treatment time to complete wound healing of DFU by SoC + CYWC628, compared to SoC only
from enrollment to the end of the treatment at 12 weeks
Complete wound closure and PAR in SoC patients offered treatment at the end of the 12 week primary outcome
from enrollment to the end of the treatment at 12 weeks
Evaluate DFU recurrence rate in patients with successful wound healing within 12 weeks of study treatment
DFU at the same site within 6 months of original complete wound healing (last treatment). Time to recurrence of DFU within 6 months of complete wound healing (last treatment).
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Standard of CareACTIVE_COMPARATORStandard of care used for the treatment of diabetic foot ulcers once weekly for up to 12 weeks.
SoC + Low dose CYWC628EXPERIMENTALstandard of care (SoC) + low dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks:
SoC + High dose CYWC628EXPERIMENTALstandard of care + high dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks:

Interventions

NameTypeDescription
Standard of Care (SOC)OTHERThe participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded.
SoC + Low dose CYWC628BIOLOGICALThe participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded. Low dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks
SoC + High dose CYWC628BIOLOGICALThe participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded. High dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: 1. Males or females aged 18 to 80 years inclusive at time of informed consent. 2. Diagnosed/confirmed Type 1 or 2 diabetes mellitus. 3. Presence of diabetic foot ulcer (DFU) at or below the level of the malleolus that is confined to one anatomical site and without exposure of bo...

Countries:Australia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMAug 26, 2026NCT07096934Status: NOT_YET_RECRUITING → RECRUITING
MEDIUMAug 26, 2026NCT07096934Status: NOT_YET_RECRUITING → RECRUITING